Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Milestone Pharmaceuticals Inc. has received a consensus rating of "Hold" from six analysts, with one sell, three hold, and two buy recommendations.
• The stock's average 12-month price target is $4.50, and it has experienced a recent trading decline of 3.2%.
• Institutional investors hold a significant stake in Milestone, with hedge funds owning 86.18% of the company's stock.

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) have been assigned a consensus rating of "Hold" from the six ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $4.50.

MIST has been the topic of a number of recent research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Milestone Pharmaceuticals in a research report on Saturday, September 27th. Wells Fargo & Company initiated coverage on Milestone Pharmaceuticals in a research report on Thursday, September 11th. They set an "overweight" rating and a $4.00 price target on the stock.

Milestone Pharmaceuticals Trading Down 3.2%

MIST opened at $2.11 on Monday. Milestone Pharmaceuticals has a 12-month low of $0.63 and a 12-month high of $2.75. The business's fifty day simple moving average is $1.77 and its 200-day simple moving average is $1.56. The company has a market capitalization of $179.33 million, a price-to-earnings ratio of -2.51 and a beta of 0.61.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02). On average, equities research analysts predict that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. lifted its stake in shares of Milestone Pharmaceuticals by 30.1% during the 2nd quarter. Raymond James Financial Inc. now owns 43,235 shares of the company's stock worth $84,000 after purchasing an additional 10,000 shares during the last quarter. Creative Planning lifted its stake in shares of Milestone Pharmaceuticals by 74.6% during the 2nd quarter. Creative Planning now owns 23,410 shares of the company's stock worth $45,000 after purchasing an additional 10,000 shares during the last quarter. Bay Rivers Group purchased a new stake in shares of Milestone Pharmaceuticals during the 2nd quarter worth $28,000. XTX Topco Ltd lifted its stake in shares of Milestone Pharmaceuticals by 52.7% during the 1st quarter. XTX Topco Ltd now owns 52,004 shares of the company's stock worth $42,000 after purchasing an additional 17,950 shares during the last quarter. Finally, Walleye Capital LLC purchased a new stake in shares of Milestone Pharmaceuticals during the 1st quarter worth $74,000. 86.18% of the stock is currently owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.